EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Dupilumab‐associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis

Roselie Achten iD, Judith Thijs iD, Marlot van der Wal, Chantal van Luijk, Marlies de Graaf, Daphne Bakker iD, Joke de Boer, Femke van Wijk, Marjolein de Bruin-Weller iD

Allergy · 2023

DOI: 10.1111/all.15717 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, 2023. Verfasst von Roselie Achten und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, the Netherlan…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Hypersensitivity, Eye Diseases. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sanofi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dupilumab‐associated ocular surface disease (DAOSD) is frequently reported as side effect in atopic dermatitis (AD) patients. Therefore, the aim of this study was to investigate the frequency and severity of DAOSD, ophthalmic treatment response and to learn more about the effect of dupilumab on conjunctival goblet cells (GC).

Methods

This prospective study included dupilumab‐treated AD patients between February 2020 and June 2022 from the University Medical Centre Utrecht. Patients were examined by an ophthalmologist and a dermatologist before start (baseline), and after 4 and 28 weeks of dupilumab treatment. Ophthalmological examination was assessed by the Utrecht Ophthalmic Inflammatory and Allergic disease (UTOPIA) score. DAOSD was defined as an increase in UTOPIA score of ≥3 points from baseline. To quantify conjunctival GCs and to investigate the percentage of Cytokeratin 19 (CK19)‐CD45‐Mucin 5 AC (MUC5AC)+ cells, conjunctival impression cytology samples were analysed.

Results

Ocular surface disease (OSD) was present in 91.3% ( n = 63/69) patients at baseline. DAOSD was observed in 28.9% ( n = 20/69) patients, in whom GC numbers remained stable and the percentage of CK19‐CD45‐MUC5AC+ cells decreased at onset of DAOSD compared with baseline. After 28 weeks of dupilumab treatment, DAOSD was seen in 14.5% ( n = 10/69) patients. Of the 85.5% ( n = 59/69) patients without DAOSD or with controlled DAOSD at Week 28, 40.7% ( n = 24/59) patients received anti‐inflammatory ophthalmic drugs.

Conclusions

Ocular surface disease is common in moderate‐to‐severe AD patients before starting dupilumab. During treatment with dupilumab DAOSD severity improves with early ophthalmic treatment. The decrease in percentage of CK19‐CD45‐MUC5AC+ cells during dupilumab treatment suggests an impairment of the GC function due to dupilumab treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicHypersensitivityEye DiseasesHumansGoblet CellsProspective StudiesAntibodies, Monoclonal, HumanizedTreatment OutcomeSeverity of Illness Index

Stichwörter der Autor:innen

atopic dermatitisdupilumabdupilumab-associated ocular surface diseasegoblet cell

Substanzen

dupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology and Allergology, National Expertise Center for Atopic Dermatitis, University Medical Center Utrecht, Utrecht, the Netherlands.
  • Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Department of Ophthalmology, University Medical Center Utrecht, Utrecht, the Netherlands.

ORCID-Profile: Roselie Achten, Judith Thijs, Daphne Bakker, Marjolein de Bruin-Weller

Förderung

  • Sanofi

Zitieren

APA

Achten, R., Thijs, J., van der Wal, M., van Luijk, C., de Graaf, M., Bakker, D., de Boer, J., van Wijk, F., & de Bruin-Weller, M. (2023). Dupilumab‐associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis. Allergy. https://doi.org/10.1111/all.15717

Vancouver

Achten R, Thijs J, van der Wal M, van Luijk C, de Graaf M, Bakker D, et al. Dupilumab‐associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis. Allergy. 2023. doi:10.1111/all.15717

BibTeX
@article{Achten2023,
  author = {Achten, Roselie and Thijs, Judith and van der Wal, Marlot and van Luijk, Chantal and de Graaf, Marlies and Bakker, Daphne and de Boer, Joke and van Wijk, Femke and de Bruin-Weller, Marjolein},
  title = {Dupilumab‐associated ocular surface disease in atopic dermatitis patients: Clinical characteristics, ophthalmic treatment response and conjunctival goblet cell analysis},
  journal = {Allergy},
  year = {2023},
  doi = {10.1111/all.15717}
}
Kostenlos starten →